It has been demonstrated that in hepatocellular carcinoma (HCC) patients at advanced clinical stages, the overall survival of cases with low NBR2 expression is significantly worse compared to those with high NBR2 expression. This evidence concerns the gene NBR2 and hepatocellular carcinoma.